OKYO 파마(OKYO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.52 (+0.66%), 시가총액 $0.09B, 52주 범위 $1.34 ~ $3.27.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO 파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
OKYO 파마의 현재 주가는 $1.52 (+0.66%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
OKYO 파마의 시가총액은 약 $0.09B입니다.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical pr